It has also improved on Rebetron with a drug called Peg-Intron, a "pegylated" combination of interferon and polyethylene glycol (Peg for short).

FORBES: The Next HIV?

In September Schering announced plans for a 2, 880-person trial to prove once and for all that Peg-Intron is a better drug.

FORBES: Magazine Article

Pegasys' only competition will be PEG-Intron, a very similar drug made by Kenilworth, N.

FORBES: Roche And Schering's Desperate Duel

Peg-Intron cuts injections to once a week and bumps the cure rate above 50%.

FORBES: The Next HIV?

Its hepatitis C medicines, Rebetol and Peg-Intron, are facing tough competition from a new entrant from Roche , a Basel, Switzerland-based drug giant.

FORBES: Hassan Taps His Buddy List

Last summer sales of Schering-Plough's only other big seller, the hepatitis drug Peg-Intron, nose-dived as doctors switched to a new and more convenient compound from Roche Holding.

FORBES: Pills and Poker

Schering-Plough faces legal investigations into its disclosure and pricing practices, a dismal relationship with the Food and Drug Administration and cutthroat competition on its best-selling drug, a treatment for hepatitis C called Peg-Intron.

FORBES: Magazine Article

PEG-Intron has already been on the market for almost two years, making it a well-established product.

FORBES: Hepatitis C Marketing Wars Begin

Basel, Switzerland-based Roche has started a price war between its hepatitis C drug, Pegasys, and Schering-Plough's Peg-Intron.

FORBES: Schering-Plough's Incredible Shrinking Profits